LCA’s Research Showcased on a World Stage

2018-10-04T13:38:47+00:00September 18th, 2018|Hot Topics, News|

The Lung Cancer Alliance team is heading to IASLC's World Conference on Lung Cancer (WCLC), Toronto, Canada from September 23-28, 2018 and will be presenting on hot topics in the field of lung cancer including: clinical trials, long-term survivorship, stigma, advocacy and much more! Below are details on our whereabouts and what we will be discussing.  If you are in Toronto, stop by! For news and updates live from the event, follow us on Twitter at @LCAorg or via the event [...]

An Unexpected Path

2018-09-11T17:12:25+00:00September 11th, 2018|Hot Topics, News|

Shanen M. Sherrer, PhD By Shanen M. Sherrer, PhD Shanen M. Sherrer, PhD, is the Assistant Professor of Biochemistry, Department of Chemistry and Biochemistry, St. Mary’s College of Maryland. We interviewed Dr. Sherrer to find out about her career as a cancer researcher, how attending a Shine A Light event impacted her work and what’s on the horizon in lung cancer research. Q: What attracted you to the field of cancer research? A: I always knew that I [...]

A Message from Our President

2018-03-21T20:28:20+00:00December 19th, 2017|Hot Topics, News|

Dear Friend, As 2017 prepares to come to a close, let’s take this moment to reflect upon what we have accomplished to improve survivorship, provide support and bring our community together in a lasting and meaningful way. Together we secured more federal research funding, helped patients navigate clinical trials and get molecular testing, launched a new website to make finding information easier and faster, expanded our network of screening centers of excellence across the country to over 530 so that [...]

Science & Research Advances in 2017

2018-03-21T20:37:45+00:00December 14th, 2017|Hot Topics, News|

By Jennifer C. King, PhD, Director of Science & Research at Lung Cancer Alliance Research on the treatment of lung cancer has been moving quickly and 2017 was no different. Precision medicine was a key theme this year - there have been many treatment advances that depend on the gene changes in each person’s lung cancer. Approvals of New Drugs and Molecular Tests The United States Food and Drug Administration (FDA) has approved brand new drugs for non-small cell lung [...]

November is Just the Beginning

2018-03-21T21:05:02+00:00December 7th, 2017|Hot Topics, News|

LCAM 2017 This November was the most impactful Lung Cancer Awareness Month (LCAM) to date! With your efforts, time and ongoing support we were able to reach more people, raise more awareness and ignite more change than ever before. Thanks to all those who came out to an LCAM event. Shine a Light on Lung Cancer, the largest coordinated lung cancer event, spanned across 167 hospitals nationwide with about 8,350 attendees, while volunteer-driven fundraisers raised over $4,000. The online community [...]

LCA Partners with Memorial Sloan Kettering Cancer Center and the New York University School of Medicine on CASTL Initiative

2018-03-23T15:27:23+00:00November 6th, 2017|Hot Topics, News|

Monday, November 6, 2017 – Today, Lung Cancer Alliance (LCA) joins the Memorial Sloan Kettering Cancer Center (MSK) and the NYU School of Medicine (NYU) to announce the launch of the Cessation And Screening To Save Lives (CASTL) Initiative. The project, which is supported by funding from the National Cancer Institute, will examine how to best leverage lung cancer screening to promote smoking cessation among individuals at high-risk for lung cancer. CASTL will be co-led by Jamie Ostroff, PhD, Chief [...]

FDA Approves First Combination of Chemotherapy and Immunotherapy for Lung Cancer Patients

2018-03-23T17:15:28+00:00September 28th, 2017|Hot Topics|

Today, the Food and Drug Administration (FDA) approved the first combination of chemotherapy and immunotherapy for patients with lung cancer. Patients with metastatic, nonsquamous, non-small cell lung cancer can now take Keytruda (pembrolizumab) immunotherapy along with chemotherapy (pemetrexed and carboplatin) as a first line of treatment for their lung cancer. This approval was based on data from the KEYNOTE-21 trial showing that patients treated with the combination therapy had a 55% response rate, compared to 29% with chemotherapy alone. With [...]

No announcement available or all announcement expired.